Spark Therapeutics, Inc. (ONCE) EPS Estimated At $-0.45; Botswana Diamonds plc (LON:BOD) Covered By 2 Bulls

April 20, 2018 - By reb123z

Spark Therapeutics, Inc. (NASDAQ:ONCE) Logo

Among 2 analysts covering Botswana Diamonds PLC (LON:BOD), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Botswana Diamonds PLC had 40 analyst reports since September 3, 2015 according to SRatingsIntel. The firm earned “Speculative Buy” rating on Tuesday, April 25 by Northland Capital. The stock has “Buy” rating by Northland Capital on Monday, February 27. Northland Capital maintained the shares of BOD in report on Thursday, December 1 with “Speculative Buy” rating. The firm has “Speculative Buy” rating by Northland Capital given on Friday, September 9. The firm earned “Corporate” rating on Friday, December 18 by Northland Capital. The company was maintained on Monday, March 27 by Northland Capital. On Thursday, November 19 the stock rating was maintained by Northland Capital with “Speculative Buy”. Dowgate Capital maintained the shares of BOD in report on Monday, February 6 with “Buy” rating. As per Thursday, October 5, the company rating was maintained by Northland Capital. The stock of Botswana Diamonds plc (LON:BOD) has “Speculative Buy” rating given on Monday, February 6 by Northland Capital. See Botswana Diamonds plc (LON:BOD) latest ratings:

21/03/2018 Broker: Northland Capital Rating: Speculative Buy Maintain
14/02/2018 Broker: Northland Capital Rating: Speculative Buy Maintain
25/01/2018 Broker: Northland Capital Rating: Speculative Buy Maintain
17/11/2017 Broker: Northland Capital Rating: Speculative Buy Maintain
26/10/2017 Broker: Northland Capital Rating: Speculative Buy Maintain
24/10/2017 Broker: Northland Capital Rating: Speculative Buy Maintain

Analysts expect Spark Therapeutics, Inc. (NASDAQ:ONCE) to report $-0.45 EPS on May, 8.They anticipate $1.25 EPS change or 73.53% from last quarter’s $-1.7 EPS. After having $-1.73 EPS previously, Spark Therapeutics, Inc.’s analysts see -73.99% EPS growth. The stock increased 0.12% or $0.1 during the last trading session, reaching $81.26. About 321,700 shares traded. Spark Therapeutics, Inc. (NASDAQ:ONCE) has risen 21.52% since April 20, 2017 and is uptrending. It has outperformed by 9.97% the S&P500.

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company has market cap of $3.02 billion. The Company’s products include voretigene neparvovec, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or biallelic mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. It currently has negative earnings. The company's products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A.

Investors sentiment decreased to 1.43 in 2017 Q4. Its down 1.51, from 2.94 in 2017Q3. It turned negative, as 41 investors sold Spark Therapeutics, Inc. shares while 26 reduced holdings. 41 funds opened positions while 55 raised stakes. 35.76 million shares or 6.30% more from 33.64 million shares in 2017Q3 were reported. Envestnet Asset Mngmt has invested 0% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Sabby Mngmt Ltd Liability Com holds 110,827 shares or 0.53% of its portfolio. New York-based Amer Grp Inc has invested 0% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Moreover, Edge Wealth Mngmt Limited Liability has 0.01% invested in Spark Therapeutics, Inc. (NASDAQ:ONCE) for 900 shares. Winslow Evans Crocker, Massachusetts-based fund reported 60 shares. Goldman Sachs Gp accumulated 0% or 355,372 shares. Moreover, Susquehanna Int Grp Inc Llp has 0% invested in Spark Therapeutics, Inc. (NASDAQ:ONCE). First Mercantile Trust has 0% invested in Spark Therapeutics, Inc. (NASDAQ:ONCE). Macquarie reported 175,270 shares or 0.02% of all its holdings. Eventide Asset Mgmt Lc invested 0.87% of its portfolio in Spark Therapeutics, Inc. (NASDAQ:ONCE). Landscape Cap Management Ltd Llc stated it has 27,073 shares or 0.12% of all its holdings. Dekabank Deutsche Girozentrale owns 13,800 shares or 0.01% of their US portfolio. Evercore Wealth Lc holds 0.01% of its portfolio in Spark Therapeutics, Inc. (NASDAQ:ONCE) for 2,700 shares. Altrinsic Global Advsrs Llc accumulated 30,000 shares or 0.06% of the stock. State Of Wisconsin Inv Board has 26,500 shares for 0% of their portfolio.

Among 25 analysts covering Spark Therapeutics (NASDAQ:ONCE), 16 have Buy rating, 2 Sell and 7 Hold. Therefore 64% are positive. Spark Therapeutics had 68 analyst reports since August 21, 2015 according to SRatingsIntel. The stock has “Sell” rating by Zacks on Wednesday, September 2. Cantor Fitzgerald maintained Spark Therapeutics, Inc. (NASDAQ:ONCE) rating on Monday, July 17. Cantor Fitzgerald has “Buy” rating and $9400 target. The stock has “Outperform” rating by BMO Capital Markets on Friday, October 13. Wedbush upgraded Spark Therapeutics, Inc. (NASDAQ:ONCE) on Tuesday, December 12 to “Hold” rating. The stock of Spark Therapeutics, Inc. (NASDAQ:ONCE) earned “Buy” rating by Cantor Fitzgerald on Friday, June 3. Cantor Fitzgerald maintained Spark Therapeutics, Inc. (NASDAQ:ONCE) on Monday, December 11 with “Buy” rating. Barclays Capital initiated Spark Therapeutics, Inc. (NASDAQ:ONCE) rating on Wednesday, September 6. Barclays Capital has “Buy” rating and $104.0 target. The stock of Spark Therapeutics, Inc. (NASDAQ:ONCE) earned “Buy” rating by Cowen & Co on Wednesday, August 2. The company was maintained on Wednesday, December 13 by Bernstein. Zacks downgraded the shares of ONCE in report on Friday, August 21 to “Hold” rating.

Spark Therapeutics, Inc. (NASDAQ:ONCE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: